ClinicalTrials.gg
Active, not recruitingNCT07298434DECLARATIONUpdated Jun 10, 2026

Study of VYD2311 for the Prevention of COVID-19

A Phase 3 interventional study of VYD2311-SD and VYD2311-MD in COVID-19, sponsored by Invivyd, Inc.. Active, not recruiting at 20 sites in United States. Open to participants aged 12 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Invivyd, Inc. · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,770
Allocation
Randomized
Ages
12 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Planned enrollment
130th of 1,321
1,770 · median 91
Started
2026
with 21 others
Phase 3
174 of 1,859
11 open now
Primary completion
2026-08
later than 68 of 208 live
Registered
1,833rd of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 130th largest by planned enrollment of the 1,321 interventional ones that give a count, is one of 22 that started in 2026, is one of 174 in phase 3, reaches primary completion later than 68 of the 208 other live ones, and was the 1,833rd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adults and adolescents at least 12 years old. Participants in this study will be given a "study drug" that will be either VYD2311 or placebo.

The study drug will be given as a shot into the muscle in the participant's upper thigh or upper arm once a month with a total of 3 shots during the study.

This study will help researchers see how well VYD2311 works to prevent COVID-19 during the 90 days after the first shot. The study will also look at the safety and tolerability of VYD2311, how the study drug is processed by the body (pharmacokinetics), how the immune system reacts to the study drug (immunogenicity), and how well VYD2311 can block the virus from infecting cells (neutralization). To do these tests, your blood will be drawn at certain times during the study.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • COVID
  • COVID-19
  • mAb
  • antibody
  • COVID-19 prevention
  • VYD2311
  • SARS-CoV-2 Monocloncal Antibody
04

Who can participate

Ages eligible
12 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all the following criteria apply:

  1. Is an adult aged ≥18 years or an adolescent aged 12 to \<18 years weighing at least 40 kg at the time of Screening. Note: Adolescent enrollment is allowed only if permitted by the local health authorities and local ethics committees.
  2. Has uninterrupted access to a device (eg, mobile phone, tablet) enabled to receive study reminders (eg, SMS text messages). The parent/guardian of adolescent participants will receive the study reminders.
  3. Provides written documentation of by signing a current IEC/IRB-approved ICF at the time of Screening. In the case of adolescents, parental informed consent and adolescent assent must also be obtained.
  4. Is able to understand and comply with study requirements/procedures (if applicable, with assistance by a caregiver, surrogate, or LAR) based on the assessment of the Investigator.
  5. For participants assigned female sex at birth:

    1. Is not of , OR
    2. Is of childbearing potential and practicing adequate for at least 7 days before dosing on Day 1, agrees to practice adequate contraception through 6 months after any dosing, and has a negative pregnancy test result on Day 1.

Note: Pregnant participants will be eligible for enrollment after iDMC review of safety data only upon Sponsor communication to sites and only in regions permitted by local health authorities and local ethics committees. If pregnant participants are eligible for enrollment, this criterion is no longer applicable.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Prior receipt of VYD2311 or pemivibart (VYD222) within 12 months before Day 1 or plans to receive pemivibart within 90 days after Day 1.
  2. Prior receipt of convalescent plasma or a mAb to SARS-CoV-2 active against currently circulating variants within 120 days before Day 1 or plans to receive convalescent plasma or an active SARS-CoV-2 mAb within 90 days after Day 1.
  3. Tests positive for current SARS-CoV-2 infection by local RAT or RT-PCR on Day 1.
  4. Prior known or suspected SARS-CoV-2 infection within 120 days before Day 1.
  5. Exposure to someone with known or suspected SARS-CoV-2 infection in the 5 days before Day 1.
  6. Is acutely ill, including symptoms suggestive of SARS-CoV-2 infection, in the opinion of the investigator or has a fever ≥38 o C (≥100.4 o F) within 3 days of Day 1.
  7. Received or plans to receive a non-COVID-19 vaccine within 7 days before or after each dose of study drug.

NOTE: Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,770 participants (estimated)

Study arms

  • Active comparator
    VYD2311-SD (single dose)

    VYD2311 administered via IM injection on Day 1, followed by placebo injection (0.9% sodium chloride \[normal saline\]) on Day 30 and Day 60

    Drug: VYD2311-SD

  • Active comparator
    VYD2311-MD (multidose)

    VYD2311 administered via IM injection on Day 1, Day 30, and Day 60

    Drug: VYD2311-MD

  • Placebo comparator
    Placebo

    Normal saline administered by IM injection on Day 1, Day 30, and Day 60

    Drug: Placebo

Interventions

  • VYD2311-SD (single-dose arm): Intramuscular injection dosing on Day 1 with VYD2311 and Intramuscular injection dosing Placebo (normal saline) on Day 30 and Day 60

  • VYD2311-MD (multi-dose): Intramuscular injection dosing on Day 1, Day 30, and Day 60 with VYD2311

  • DrugPlacebo

    Intramuscular injection dosing on Day 1, Day 30, and Day 60 with Placebo (Normal Saline)

06

What researchers measure

Primary outcomes

  1. RT-PCR-confirmed symptomatic COVID-19 through Day 90

    Time frame: 90 days

Secondary outcomes

  1. Assessment of safety based on treatment-emergent adverse events, injection site reactions, and hypersensitivity reactions through Day 90

    Time frame: 90 days

  2. Serum concentrations of VYD2311 through Day 90

    Time frame: 90 days

  3. Incidence of ADAs against VYD2311 through Day 90

    Time frame: 90 days

  4. Calculated sVNA titers (VYD2311 serum concentration/variant IC50) against relevant SARS-CoV-2 variants through Day 90

    Time frame: 90 days

07

Study locations

20 sites
  • Invivyd Investigative Site
    Long Beach, California 90806, United States
  • Inviviyd Investigative Site
    San Diego, California 92103, United States
  • Invivyd Investigative Site
    Orlando, Florida 32819, United States
  • Invivyd Investigative Site
    Hinesville, Georgia 31313, United States
  • Invivyd Investigative Site
    Melrose Park, Illinois 60160, United States
  • Invivyd Investigative Site
    Lenexa, Kansas 66219, United States
  • Invivyd Investigative Site
    Silver Spring, Maryland 20904, United States
  • Invivyd Investigative Site
    Burlington, Massachusetts 01803, United States
  • Invivyd Investigative Site
    Southfield, Michigan 48034, United States
  • Invivyd Investigative Site
    Maplewood, Minnesota 55109, United States
  • Invivyd Investigative Site
    Independence, Missouri 64055, United States
  • Invivyd Investigative Site
    Jersey City, New Jersey 07306, United States
  • Invivyd Investigative Site
    The Bronx, New York 10455, United States
  • Invivyd Investigative Site
    Philadelphia, Pennsylvania 19107, United States
  • Invivyd Investigative Site
    Myrtle Beach, South Carolina 29572, United States
  • Invivyd Investigative Site
    Goodlettsville, Tennessee 37072, United States
  • Invivyd Investigative Site
    Houston, Texas 77065, United States
  • Invivyd Investigative Site
    Houston-2, Texas 77065, United States
  • Invivyd Investigative Site
    Irving, Texas 75061, United States
  • Invivyd Investigative Site
    Sugar Land, Texas 46254, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2026, 7 months after the start.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 7 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Dec 23, 2025
StartActual
Jan 8, 2026
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07298434
Lead sponsor
Invivyd, Inc.
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Jan 8, 2026
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Jun 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibramvibart

Start the discussion